Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP +35.00% EV-to-OCF is -2.19 as of Jul. 22, 2026. The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Regen BioPharma ranks worse than 57.02% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Regen BioPharma's Enterprise Value is $1.04 Mil.
Regen BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48 Mil. Therefore, Regen BioPharma's EV-to-OCF for today is -2.19.
The historical rank and industry rank for Regen BioPharma's EV-to-OCF or its related term are showing as below:
RGBP'
s EV-to-OCF Range Over the Past 10 Years
Min: -1382.43 Med: -4.69 Max: 268.62
Current: -2.19
During the past 13 years, the highest EV-to-OCF of Regen BioPharma was 268.62. The lowest was -1382.43. And the median was -4.69.
RGBP's EV-to-OCF is ranked worse than 57.02% of 1410
companies
in the Biotechnology industry
Industry Median: -3.325
vs RGBP: -2.19
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regen BioPharma's PE Ratio (TTM) for today is calculated as:
Regen BioPharma's share price for today is $0.000135.
Regen BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Regen BioPharma EV-to-OCF Related Terms
Regen BioPharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regen BioPharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's EV-to-OCF falls into.
Regen BioPharma's current Enterprise Value is $1.04 Mil.
Regen BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a EV-to-OCF of -2.19 as of Jul. 22, 2026. According to the industry distribution chart, Regen BioPharma ranks #804 out of 1410 companies in the Biotechnology industry, placing it in the top 57%.
Is Regen BioPharma's EV-to-OCF too high?
Regen BioPharma's current EV-to-OCF is -2.19. Based on the distribution chart, Regen BioPharma ranks #804 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regen BioPharma's EV-to-OCF compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #804 out of 1410 companies for EV-to-OCF. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Regen BioPharma's current EV-to-OCF is -2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current EV-to-OCF is -2.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current EV-to-OCF is -2.19 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
